{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:41:14Z","timestamp":1793832074393,"version":"4.6.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intravitreal (IVT) anti\u2013vascular endothelial growth factor (anti-VEGF) therapies are the standard of care for retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Despite the favourable efficacy and safety profiles of these therapies, decreasing the treatment burden is still an unmet need because frequent injections may be required over many years. The pharmacokinetic and pharmacodynamic properties of IVT therapies, such as ocular half-life and clearance, can affect the duration of VEGF suppression and thus influence clinical outcomes. Although some properties are inherent to the drug molecule (such as molecular weight, binding affinity and potency) and cannot be altered without changing the structure of the molecule, other factors (such as the dose of the drug) can be increased, which may prolong VEGF suppression time in the eye and, in turn, may lead to a more durable effect of the drug. In addition to pharmacokinetic and pharmacodynamic properties, individual patient factors such as age, surgical history and disease status can also affect the pharmacokinetics, pharmacodynamics and observed effectiveness of a drug. This article reviews the key pharmacological properties of IVT anti-VEGF treatments for nAMD and DMO often referred to in the literature, and aims to elucidate their meaning and clinical relevance for managing retinal diseases.<\/jats:p>","DOI":"10.1038\/s41433-026-04540-y","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T01:00:38Z","timestamp":1779325238000},"page":"1431-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist"],"prefix":"10.1038","volume":"40","author":[{"given":"Samia","family":"Ezzine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0213-6253","authenticated-orcid":false,"given":"Richard","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-4512","authenticated-orcid":false,"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-4067","authenticated-orcid":false,"given":"Praveen J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":false,"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9000-8104","authenticated-orcid":false,"given":"Zinab","family":"Keshk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-3423","authenticated-orcid":false,"given":"Thomas","family":"Eissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8030-0051","authenticated-orcid":false,"given":"Joachim","family":"H\u00f6chel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9115-1220","authenticated-orcid":false,"given":"Rose","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-6040","authenticated-orcid":false,"given":"Peter","family":"Morgan-Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"4540_CR1","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik J-F, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123:2376\u201385.","journal-title":"Ophthalmology"},{"key":"4540_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"4540_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57\u201365.e5.","journal-title":"Ophthalmology"},{"key":"4540_CR4","unstructured":"Novartis Europharm Limited. Lucentis 10 mg\/ml solution for injection \u2013 summary of product characteristics; updated 17 December 2025. Novartis Europharm Limited; Dublin, Ireland."},{"key":"4540_CR5","unstructured":"European Commission. Eylea Product information (EMA\/VR\/0000264981). https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h797.htm."},{"key":"4540_CR6","unstructured":"Novartis Europharm Limited. Beovu 120 mg\/ml solution for injection \u2013 summary of product characteristics; updated 27 January 2026. Novartis Europharm Limited; Dublin, Ireland."},{"key":"4540_CR7","unstructured":"Roche Registration GmbH. Vabysmo 120 mg\/ml solution for injection \u2013 summary of product characteristics; updated 6 January 2026. Roche Registration GmbH; Grenzach-Wyhlen, Germany."},{"key":"4540_CR8","unstructured":"Outlook Therapeutics Limited. Lytenava 25 mg\/ml solution for injection \u2013 summary of product characteristics; updated 9 February 2026. Outlook Therapeutics Limited; Dublin, Ireland."},{"key":"4540_CR9","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s12325-022-02119-z","volume":"39","author":"JG Garweg","year":"2022","unstructured":"Garweg JG, \u0160tefanickova J, Hoyng C, Niesen T, Schmelter T, Leal S, et al. Dosing regimens of intravitreal aflibercept for diabetic macular edema beyond the first year: VIOLET, a prospective randomized trial. Adv Ther. 2022;39:2701\u201316.","journal-title":"Adv Ther"},{"key":"4540_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21:133.","journal-title":"J Transl Med"},{"key":"4540_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243:1\u20138.","journal-title":"Ophthalmologica"},{"key":"4540_CR12","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/OPTH.S409103","volume":"17","author":"G Reitan","year":"2023","unstructured":"Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesb\u00f8ll C. Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway. Clin Ophthalmol. 2023;17:1465\u201374.","journal-title":"Clin Ophthalmol"},{"key":"4540_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajo.2017.03.005","volume":"177","author":"H Senra","year":"2017","unstructured":"Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol. 2017;177:213\u201324.","journal-title":"Am J Ophthalmol"},{"key":"4540_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/eye.2017.1","volume":"31","author":"B Foot","year":"2017","unstructured":"Foot B, MacEwen C. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome. Eye (Lond). 2017;31:771\u20135.","journal-title":"Eye (Lond)"},{"key":"4540_CR15","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s41433-019-0411-5","volume":"33","author":"M Hingorani","year":"2019","unstructured":"Hingorani M. The invisible ophthalmologist. Eye (Lond). 2019;33:1193\u20134.","journal-title":"Eye (Lond)"},{"key":"4540_CR16","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina. 2021;41:1911\u201320.","journal-title":"Retina"},{"key":"4540_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR; a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"4540_CR18","first-page":"41","volume":"3","author":"A Skelly","year":"2019","unstructured":"Skelly A, Bezlyak V, Liew G, Kap E, Sagkriotis A. Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients. Vis (Basel). 2019;3:41.","journal-title":"Vis (Basel)"},{"key":"4540_CR19","first-page":"67","volume":"15","author":"S Kalra","year":"2019","unstructured":"Kalra S, Kamaruddin NA, Visvanathan J, Santani R. Defining disease progression and drug durability in type 2 diabetes mellitus. Eur Endocrinol. 2019;15:67\u20139.","journal-title":"Eur Endocrinol"},{"key":"4540_CR20","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OPTH.S231801","volume":"15","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, et al. Angiopoietins as Potential Targets in Management of Retinal Disease. Clin Ophthalmol. 2021;15:3747\u201355.","journal-title":"Clin Ophthalmol"},{"key":"4540_CR21","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.37765\/ajmc.2022.88853","volume":"28","author":"JE Kim","year":"2022","unstructured":"Kim JE. Exploring neovascular age-related macular degeneration and diabetic macular edema and advances in treatment. Am J Manag Care. 2022;28:S35\u2013S43.","journal-title":"Am J Manag Care"},{"key":"4540_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00603-y","volume":"10","author":"ASA Sakini","year":"2024","unstructured":"Sakini ASA, Hamid AK, Alkhuzaie ZA, Al-Aish ST, Al-Zubaidi S, Tayem AA, et al. Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights. Int J Retin Vitreous. 2024;10:83.","journal-title":"Int J Retin Vitreous"},{"key":"4540_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.survophthal.2024.07.006","volume":"69","author":"S Vujosevic","year":"2024","unstructured":"Vujosevic S, Lupidi M, Donati S, Astarita C, Gallinaro V, Pilotto E. Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration. Surv Ophthalmol. 2024;69:870\u201381.","journal-title":"Surv Ophthalmol"},{"key":"4540_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnmt.117.199588","volume":"46","author":"GM Currie","year":"2018","unstructured":"Currie GM. Pharmacology, part 1: introduction to pharmacology and pharmacodynamics. J Nucl Med Technol. 2018;46:81\u20136.","journal-title":"J Nucl Med Technol"},{"key":"4540_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2016_25","volume":"242","author":"Y Park","year":"2017","unstructured":"Park Y, Ellis D, Mueller B, Stankowska D, Yorio T. Principles of ocular pharmacology. Handb Exp Pharm. 2017;242:3\u201330.","journal-title":"Handb Exp Pharm"},{"key":"4540_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jsps.2016.07.002","volume":"25","author":"MS Salahudeen","year":"2017","unstructured":"Salahudeen MS, Nishtala PS. An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice. Saudi Pharm J. 2017;25:165\u201375.","journal-title":"Saudi Pharm J"},{"key":"4540_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jpha.2019.11.006","volume":"10","author":"O Begou","year":"2020","unstructured":"Begou O, Drabert K, Theodoridis G, Tsikas D. GC-NICI-MS analysis of acetazolamide and other sulfonamide (R-SO2-NH2) drugs as pentafluorobenzyl derivatives [R-SO2-N(PFB)2] and quantification of pharmacological acetazolamide in human urine. J Pharm Anal. 2020;10:49\u201359.","journal-title":"J Pharm Anal"},{"key":"4540_CR28","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/aps.2012.51","volume":"33","author":"L Zhao","year":"2012","unstructured":"Zhao L, Ren T-H, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharm Sin. 2012;33:1339\u201347.","journal-title":"Acta Pharm Sin"},{"key":"4540_CR29","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296\u2013304.","journal-title":"Ophthalmology"},{"key":"4540_CR30","doi-asserted-by":"crossref","unstructured":"Wong DT, Aboobaker S, Maberley D, Sharma S, Yoganathan P. Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations. BMJ Open Ophthalmol. 2025;10:e001967.","DOI":"10.1136\/bmjophth-2024-001967"},{"key":"4540_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11095-016-2037-7","volume":"34","author":"W Schmitt","year":"2017","unstructured":"Schmitt W. Estimation of intra-vitreal half-lifes in the rabbit eye with semi-mechanistic equations. Pharm Res. 2017;34:49\u201357.","journal-title":"Pharm Res"},{"key":"4540_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ab.2004.02.027","volume":"330","author":"MJ Cannon","year":"2004","unstructured":"Cannon MJ, Papalia GA, Navratilova I, Fisher RJ, Roberts LR, Worthy KM, et al. Comparative analyses of a small molecule\/enzyme interaction by multiple users of Biacore technology. Anal Biochem. 2004;330:98\u2013113.","journal-title":"Anal Biochem"},{"key":"4540_CR33","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2012.0835","volume":"10","author":"PL Kastritis","year":"2013","unstructured":"Kastritis PL, Bonvin AM. On the binding affinity of macromolecular interactions: daring to ask why proteins interact. J R Soc Interface. 2013;10:20120835.","journal-title":"J R Soc Interface"},{"key":"4540_CR34","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond). 2018;32:1010\u201320.","journal-title":"Eye (Lond)"},{"key":"4540_CR35","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/ijnp\/pyy071","volume":"21","author":"KA Berg","year":"2018","unstructured":"Berg KA, Clarke WP. Making sense of pharmacology: inverse agonism and functional selectivity. Int J Neuropsychopharmacol. 2018;21:962\u201377.","journal-title":"Int J Neuropsychopharmacol"},{"key":"4540_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ab.2016.06.025","volume":"508","author":"S Aykul","year":"2016","unstructured":"Aykul S, Martinez-Hackert E. Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. Anal Biochem. 2016;508:97\u2013103.","journal-title":"Anal Biochem"},{"key":"4540_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10456-016-9515-8","volume":"19","author":"DA MacDonald","year":"2016","unstructured":"MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, et al. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis. 2016;19:389\u2013406.","journal-title":"Angiogenesis"},{"key":"4540_CR38","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40123-022-00532-9","volume":"11","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Campochiaro PA, Pieramici DJ, Khanani AM, Gune S, Maia M, et al. Pharmacokinetics of the Port Delivery System with ranibizumab in the Ladder phase 2 trial for neovascular age-related macular degeneration. Ophthalmol Ther. 2022;11:1705\u201317.","journal-title":"Ophthalmol Ther"},{"key":"4540_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/tvst.10.4.9","volume":"10","author":"T Eissing","year":"2021","unstructured":"Eissing T, Stewart MW, Qian CX, Rittenhouse KD. Durability of VEGF suppression with intravitreal aflibercept and brolucizumab: using pharmacokinetic modeling to understand clinical outcomes. Transl Vis Sci Technol. 2021;10:9.","journal-title":"Transl Vis Sci Technol"},{"key":"4540_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","volume":"57","author":"EM Del Amo","year":"2017","unstructured":"Del Amo EM, Rimpel\u00e4 AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134\u201385.","journal-title":"Prog Retin Eye Res"},{"key":"4540_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.723","volume":"9","author":"ML Formica","year":"2021","unstructured":"Formica ML, Awde Alfonso HG, Palma SD. Biological drug therapy for ocular angiogenesis: anti-VEGF agents and novel strategies based on nanotechnology. Pharm Res Perspect. 2021;9:e00723.","journal-title":"Pharm Res Perspect"},{"key":"4540_CR42","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","volume":"6","author":"V Agrahari","year":"2016","unstructured":"Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6:735\u201354.","journal-title":"Drug Deliv Transl Res"},{"key":"4540_CR43","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/psp4.12342","volume":"7","author":"T Eissing","year":"2018","unstructured":"Eissing T. Allometric considerations on proteins administered intravitreally to children. CPT Pharmacomet Syst Pharm. 2018;7:703\u20135.","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"4540_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/pharmaceutics12030269","volume":"12","author":"R Varela-Fern\u00e1ndez","year":"2020","unstructured":"Varela-Fern\u00e1ndez R, D\u00edaz-Tom\u00e9 V, Luaces-Rodr\u00edguez A, Conde-Penedo A, Garc\u00eda-Otero X, Luzardo-\u00c1lvarez A, et al. Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations. Pharmaceutics. 2020;12:269.","journal-title":"Pharmaceutics"},{"key":"4540_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.exer.2015.12.013","volume":"145","author":"M Dithmer","year":"2016","unstructured":"Dithmer M, Hattermann K, Pomarius P, Aboul Naga SH, Meyer T, Mentlein R, et al. The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium. Exp Eye Res. 2016;145:187\u2013205.","journal-title":"Exp Eye Res"},{"key":"4540_CR46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1167\/tvst.11.10.36","volume":"11","author":"W Schubert","year":"2022","unstructured":"Schubert W, Terjung C, Rafique A, Romano C, Ellinger P, Rittenhouse KD. Evaluation of molecular properties versus in vivo performance of aflibercept, brolucizumab, and ranibizumab in a retinal vascular hyperpermeability model. Transl Vis Sci Technol. 2022;11:36.","journal-title":"Transl Vis Sci Technol"},{"key":"4540_CR47","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1136\/bjophthalmol-2015-308264","volume":"100","author":"S Fauser","year":"2016","unstructured":"Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100:1494\u20138.","journal-title":"Br J Ophthalmol"},{"key":"4540_CR48","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ajo.2014.05.025","volume":"158","author":"S Fauser","year":"2014","unstructured":"Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158:532\u20136.","journal-title":"Am J Ophthalmol"},{"key":"4540_CR49","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.ophtha.2012.07.041","volume":"119","author":"PS Muether","year":"2012","unstructured":"Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology. 2012;119:2082\u20136.","journal-title":"Ophthalmology"},{"key":"4540_CR50","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","volume":"13","author":"LA Hutton-Smith","year":"2016","unstructured":"Hutton-Smith LA, Gaffney EA, Byrne HM, Maini PK, Schwab D, Mazer NA. A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration. Mol Pharm. 2016;13:2941\u201350.","journal-title":"Mol Pharm"},{"key":"4540_CR51","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"4540_CR52","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403:1153\u201363.","journal-title":"Lancet"},{"key":"4540_CR53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"4540_CR54","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Su\u00f1er IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046\u201356.","journal-title":"Ophthalmology"},{"key":"4540_CR55","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","volume":"121","author":"AC Ho","year":"2014","unstructured":"Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181\u201392.","journal-title":"Ophthalmology"},{"key":"4540_CR56","first-page":"3154","volume":"65","author":"PK Kaiser","year":"2024","unstructured":"Kaiser PK, Turner KC, Bihorel S, Chiu J, Harnisch L, Chittenden J, et al. Population pharmacokinetic modeling and simulation of ocular clearance for aflibercept 8 mg and 2 mg and association with durability of effect. Invest Ophthalmol Vis Sci. 2024;65:3154.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4540_CR57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171\u201385.","journal-title":"Angiogenesis"},{"key":"4540_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100954","volume":"84","author":"A Uemura","year":"2021","unstructured":"Uemura A, Fruttiger M, D\u2019Amore PA, De Falco S, Joussen AM, Sennlaub F, et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res. 2021;84:100954.","journal-title":"Prog Retin Eye Res"},{"key":"4540_CR59","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R Jr., Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904\u201314.","journal-title":"Ophthalmology"},{"key":"4540_CR60","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.oret.2024.05.021","volume":"9","author":"PA Campochiaro","year":"2025","unstructured":"Campochiaro PA, Eichenbaum D, Chang MA, Clark WL, Graff JM, Le Pogam S, et al. Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmol Retin. 2025;9:144\u201355.","journal-title":"Ophthalmol Retin"},{"key":"4540_CR61","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaophthalmol.2025.0006","volume":"143","author":"AM Khanani","year":"2025","unstructured":"Khanani AM, Campochiaro PA, Graff JM, Marcus DM, Miller D, Mittra RA, et al. Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. JAMA Ophthalmol. 2025;143:326\u201335.","journal-title":"JAMA Ophthalmol"},{"key":"4540_CR62","doi-asserted-by":"crossref","unstructured":"Rowe LW, Ciulla TA Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond. Genes (Basel). 2024;15.","DOI":"10.3390\/genes15060720"},{"key":"4540_CR63","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/IAE.0b013e3182753b12","volume":"33","author":"JB Christoforidis","year":"2013","unstructured":"Christoforidis JB, Williams MM, Wang J, Jiang A, Pratt C, Abdel-Rasoul M, et al. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina. 2013;33:946\u201352.","journal-title":"Retina"},{"key":"4540_CR64","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1167\/iovs.15-17279","volume":"56","author":"Y Niwa","year":"2015","unstructured":"Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M. Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci. 2015;56:6501\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4540_CR65","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.1167\/iovs.12-10164","volume":"53","author":"M Kakinoki","year":"2012","unstructured":"Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci. 2012;53:5877\u201380.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4540_CR66","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/02713683.2022.2119254","volume":"48","author":"D Mishra","year":"2023","unstructured":"Mishra D, Gade S, Glover K, Sheshala R, Singh TRR. Vitreous humor: composition, characteristics and implication on intravitreal drug delivery. Curr Eye Res. 2023;48:208\u201318.","journal-title":"Curr Eye Res"},{"key":"4540_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-014-0022-z","volume":"4","author":"M Radhika","year":"2014","unstructured":"Radhika M, Mithal K, Bawdekar A, Dave V, Jindal A, Relhan N, et al. Pharmacokinetics of intravitreal antibiotics in endophthalmitis. J Ophthalmic Inflamm Infect. 2014;4:22.","journal-title":"J Ophthalmic Inflamm Infect"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04540-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04540-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04540-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:03:01Z","timestamp":1783440181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04540-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4540"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04540-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SE: Previously employed by Bayer Inc, Canada, now employed at PhInc. Modelling, Montr\u00e9al, Canada. RG: Travel grants and honoraria from AbbVie, Adverum, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Ocular Therapeutix and Roche. CB: Travel grants and honoraria from Alimera Sciences, Apellis, Bayer, Boehringer Ingelheim, Janssen Pharmaceuticals and Roche. PJP: Travel grants and honoraria from Bayer, Boehringer Ingelheim, Genentech, Roche. SS: Travel grants and honoraria from AbbVie, Adverum, Alimera Sciences, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Clearside Biomedical, Eyebiotech, EyePoint Pharmaceuticals, Iveric Bio, Janssen Pharmaceuticals, Kriya Therapeutics, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Ripple Therapeutics, Roche, Sanofi and Stealth BioTherapeutics. ZK, RG: Employees of Bayer plc, UK. TE, JH: Employees and shareholders of Bayer AG, Germany. PM-W: Employee of Bayer AG, Switzerland.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}